Compare HYFM & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFM | PFSA |
|---|---|---|
| Founded | 1977 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 11.1M |
| IPO Year | 2020 | N/A |
| Metric | HYFM | PFSA |
|---|---|---|
| Price | $1.98 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 97.1K | ★ 10.1M |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,443,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $1.50 | $0.10 |
| 52 Week High | $7.50 | $12.76 |
| Indicator | HYFM | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | N/A |
| Support Level | $1.51 | N/A |
| Resistance Level | $2.74 | N/A |
| Average True Range (ATR) | 0.31 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 32.11 | 0.00 |
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.